Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14579633 | 0.84 | CHEK1 (0.44) | HTTKDM4EMAPK1LMNASMN1; SMN2 | |
| SCHEMBL1192531 | 0.79 | PARP1 (0.47) | HTTKDM4ELMNAMAPTPARP1 | |
| SCHEMBL30317618 | 0.79 | PARP1 (0.47) | HTTKDM4ELMNAMAPTPARP1 | |
| SCHEMBL6956273 | 0.79 | HTT (0.53) | HTTKDM4EMAPK1LMNASMN1; SMN2 | |
| SCHEMBL12850068 | 0.76 | MAP4K4 (0.36) | HTTLMNASMN1; SMN2MAPTMAP4K4 | |
| SCHEMBL16179658 | 0.76 | EGFR (0.51) | PARP1MAP4K4 | |
| SCHEMBL217203 | 0.76 | PARP1 (0.44) | LMNAMAPTPARP1MAP4K4 | |
| SCHEMBL685458 | 0.76 | MAP4K4 (0.68) | MAP4K4 | |
| SCHEMBL934881 | 0.76 | LMNA (0.58) | HTTKDM4EMAPK1LMNASMN1; SMN2 | |
| SCHEMBL3734931 | 0.76 | HTT (0.49) | HTTKDM4ELMNAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230269999-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-08-24 | — | — | US | disclosed |
| CN-116444445-A | Quinazolinone compound and preparation method thereof | 河北科技大学 | 2023-07-18 | — | — | CN | disclosed |
| US-20220372054-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2022-11-24 | — | — | US | disclosed |
| CN-111116552-B | Quinazolinone compound and preparation method thereof | 河北科技大学 | 2022-10-11 | — | — | CN | disclosed |
| CN-111116552-A | Quinazolinone compound and preparation method thereof | 河北科技大学 | 2020-05-08 | — | — | CN | disclosed |
| CN-107207512-B | Tricyclic pyrazole simultaneously [1, the 5-A] pyrimidine derivatives that there is the piperidines of inhibitory activity to replace the duplication of Respiratory Syncytial Virus(RSV) (RSV) | 爱尔兰詹森科学公司 | 2019-09-10 | — | — | CN | disclosed |
| CN-107001377-B | Pyrazolo [1,5-A] pyrimidine derivatives that there is the piperidines of inhibitory activity to replace the duplication of Respiratory Syncytial Virus(RSV) (RSV) | 爱尔兰詹森科学公司 | 2019-09-10 | — | — | CN | disclosed |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| US-9981976-B2 | Piperidine substituted pyrazolo[1,5-A]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV) | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-29 | — | — | US | disclosed |
| US-9981976-B2 | Piperidine substituted pyrazolo[1,5-A]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV) | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-29 | — | — | US | disclosed |
| EP-1606255-A4 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-02-07 | — | — | EP | disclosed |
| CN-1273451-C | Piperidine MCH antagonists and their use in treatment of obesity | SCHERING CORP (US) | 2006-09-06 | — | — | CN | disclosed |
| EP-1606255-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1343761-B1 | PIPERIDINE MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY | SCHERING CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-23 | — | — | US | disclosed |
| WO-2004071460-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
| CN-1481361-A | Piperidine MCH antagonists and their use in treatment of obesity | ���鹫˾ | 2004-03-10 | — | — | CN | disclosed |
| EP-1343761-A1 | PIPERIDINE MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY | Schering Corporation (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6472394-B1 | MCH antagonists and their use in the treatment of obesity | SCHERING CORPORATION | 2002-10-29 | — | — | US | disclosed |
| WO-2002051809-A1 | PIPERIDINE MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | HTT 3669/4885KDM4E 1824/4885MAPK1 66/4885 |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | HTT 4488/4885KDM4E 4716/4885MAPK1 105/4885 |
| US-20220372054-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | ACAT1, SORD, CRAT | HTT 1491/4885KDM4E 3425/4885MAPK1 1958/4885 |
| US-20230269999-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | ACAT1, ACMSD, SLC25A21 | HTT 990/4885KDM4E 3604/4885MAPK1 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.